DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

NCT ID: NCT06382168

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-12
• Study Completion Date: 2026-06-30

Brief Summary

This Phase I/II trial evaluates the safety and preliminary efficacy of DFP-10917 combined with venetoclax in relapsed or refractory acute myeloid leukemia. DFP-10917 is given as a 14-day continuous IV infusion every 28 days, alongside a 14-day oral course of venetoclax following an initial dose ramp-up. The initial phase tests a starting dose of 4 mg/m²/day of DFP-10917 with 400 mg daily of venetoclax. The Data Monitoring Committee reviews toxicity after one treatment cycle. If DLTs are minimal, more patients are added to confirm safety. If the lower dose level shows tolerability, it proceeds to the Phase II expansion to assess the treatment's effectiveness against leukemia using a Simon's two-stage design, targeting up to 17 participants.

Detailed Description

This study is a Phase I/II, open-label trial exploring dosage and expansion cohorts to assess the safety and preliminary efficacy of DFP-10917 in combination with venetoclax for patients with relapsed or refractory acute myeloid leukemia (AML). DFP-10917 will be administered as a 14-day continuous intravenous infusion starting on Day 1, followed by a 14-day rest period, during each 28-day cycle. This will occur concurrently with venetoclax, administered orally at a dose of 400 mg daily for 14 days following a dose ramp-up phase (100 mg and 200 mg on Day 1 and 2, respectively).

In Phase I, the starting dose for DFP-10917 is 4 mg/m²/day, administered concurrently with 400 mg of venetoclax once daily for 14 days (Dose Level 1). The Data Monitoring Committee (DMC) will assess dose-limiting toxicities (DLTs) after three patients are enrolled at this dose level and the last patient has completed the 4-week safety assessment period (i.e., one cycle of the combination regimen). At Dose Level 1 (4 mg/m²/day of DFP-10917 with venetoclax 400 mg daily for 14 days), if none of the three patients experience a DLT, the study will enroll an additional three patients at this dose level to confirm the combination's safety and tolerability. If one out of three patients experiences a DLT, up to three additional patients may be enrolled. If one or fewer out of six treated patients experience a DLT at Dose Level 1, this dose will be declared the recommended Phase II dose (RP2D) and used in the Phase II expansion cohort. If two or more patients out of the total three to six patients at Dose Level 1 experience a DLT, the study will continue enrollment at Dose Level 1 (4 mg/m²/day of DFP-10917 for 14 days concurrently with venetoclax 400 mg daily for 10 days of each 28-day cycle) to determine the safety and tolerability of Dose Level -1. A patient who discontinues therapy during Cycle 1 without experiencing DLTs is considered evaluable for safety purposes only if all scheduled doses of DFP-10917 and at least 80% of the venetoclax doses were administered in the first cycle. Once the RP2D of DFP-10917 in combination with venetoclax is determined, the expansion cohort will begin enrollment to evaluate the anti-leukemia efficacy of this combination. A Simon's two-stage min-max design will be employed, with up to 17 patients expected to participate.

Conditions

Leukemia, Myeloid, Acute

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

DFP-10917 + Venetoclax for 14 days

DFP-10917 4 mg/m\^2/day with venetoclax 400 mg once daily for 14 days

Group Type: EXPERIMENTAL

DFP-10917

Intervention Type: DRUG

DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

Venetoclax

Intervention Type: DRUG

Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.

DFP-10917 + Venetoclax for 10 days

DFP-10917 4 mg/m\^2/day with venetoclax 400 mg once daily for 10 days

Group Type: EXPERIMENTAL

DFP-10917

Intervention Type: DRUG

DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

Venetoclax

Intervention Type: DRUG

Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.

Interventions

DFP-10917

DFP-10917 4 mg/m\^2/day is given as a continuous 14-day intravenous infusion, followed by a 14-day rest in each 28-day cycle.

Intervention Type: DRUG

Venetoclax

Venetoclax 400 mg once daily for 10-14 days, followed by a 14-day rest in each 28-day cycle.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Signed informed consent and ability to comply with protocol requirements.
• Histologically or pathologically confirmed diagnosis of acute myeloid leukemia based on World Health Organization classification that has relapsed after, or is refractory to, up to 2 prior induction regimens that may have included intensive chemotherapy (e.g., "7+3" cytarabine and daunorubicin), epigenetic therapy (i.e., azacitidine or decitabine with/without venetoclax), or targeted therapy (e.g., FLT-3, IDH 1/2, BCL-2, monoclonal antibody).

(Relapse is defined as reemergence of ≥5% leukemia blasts in bone marrow or ≥1% blasts in peripheral blood 90 days to 24 months after first complete remission or complete remission with incomplete hematologic recovery. Refractory acute myeloid leukemia is defined as persistent disease ≥28 days after initiation of intensive induction therapy (up to 2 induction cycles) or relapse <90 days after first complete remission or complete remission with incomplete hematologic recover. Refractory disease for patients undergoing hypomethylating agent induction is defined as lack of remission following at least 2 cycles of epigenetic therapy without reduction in bone marrow blast status).

• Adequate organ function as defined by the following laboratory values:

• Creatinine clearance >30 mL/min (by Cockcroft-Gault method),
• Total serum bilirubin <1.5 × upper limit of normal unless due to Gilbert's syndrome, leukemic organ involvement, hemolysis or considered an effect of regular blood transfusions,
• Alanine aminotransferase and aspartate aminotransferase <3 × upper limit of normal, unless due to leukemic organ involvement.
• Eastern Cooperative Oncology Group performance status of 0, 1, or 2).
• Projected life expectancy of ≥12 weeks.
• Female patients of childbearing potential must:

• Have a negative serum or urine pregnancy test prior to study treatment initiation.
• Agree to use at least 1 highly effective form of contraception during study treatment and for 3 months after the last dose.
• Male patients with female partners of childbearing potential must -- Agree to use at least 1 highly effective form of contraception during study treatment and for at least 3 months after the last dose.

Exclusion Criteria

• Any >Grade 1 persistent clinically significant toxicities from prior chemotherapy.
• Leukemic blast count >25 × 109/L. Hydroxyurea permitted to control leukocytosis.
• Known history of human immunodeficiency virus or active hepatitis B or active hepatitis C infection.
• Concomitant malignancies for which patients are receiving active therapy at the time of signing consent. Patients with adequately treated basal or squamous cell carcinoma of the skin, adequately treated carcinoma in situ (e.g., cervix), breast cancer receiving adjuvant endocrine therapy or prostate cancer not under active systemic treatment other than hormonal therapy may enroll irrespective of the time of diagnosis, with Medical Monitor approval.
• Known active central nervous system involvement by leukemia. Patients with previously diagnosed central nervous system leukemia are eligible if the central nervous system leukemia is under control and intrathecal treatment may continue throughout the study.
• Diagnosis of acute promyelocytic leukemia.
• Prior exposure to anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 14 days of the first day of study treatment or within 5 half-lives prior to first dose of study treatment. Note that hydroxyurea up to 5 g daily × 3 days is permitted to reduce elevated white blood cell (WBC) count.
• Venetoclax exposure in more than 1 prior regimen.
• Prior exposure to biologic agents (e.g., monoclonal antibodies) for anti-neoplastic intent within 14 days prior to first dose of study drug.
• Prior hematopoietic stem cell transplantation.
• Malabsorption syndrome or other condition that precludes enteral route of administration.
• Pregnancy or lactation.
• Active uncontrolled systemic infection (viral, bacterial, or fungal).
• Ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers, P-gp inhibitors, or narrow therapeutic index P-gp substrates that cannot be discontinued at least 1 week prior to start of venetoclax dosing excluding antifungal prophylaxis.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Delta-Fly Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

UCI Chao Family Comprehensive Cancer Center

Orange, California, United States

Site Status: RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, United States

Site Status: RECRUITING

University of Vermont Cancer Center

Burlington, Vermont, United States

Site Status: RECRUITING

University of Virginia Cancer Center

Charlottesville, Virginia, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Scott Frank

Role: CONTACT

sfrank1206@delta-flypharma.co.jp

+81 362311278

Facility Contacts

Kiran Naqvi, MD, MPH

Role: primary

knaqvi1@hs.uci.edu

714-456-8000

Timothy Pardee, MD

Role: primary

tspardee@wakehealth.edu

336-716-5847

Diego Adrianzen Herrera, MD

Role: primary

dadrianz@med.uvm.edu

802-656-2021

Michael Keng, MD

Role: primary

mk2pv@uvahealth.org

434-424-1505

Other Identifiers

D19-11186

Identifier Type: -

Identifier Source: org_study_id